Database→CJC-1295

Tier 2–3HormonalAnti-agingMetabolicPREMIUM

CJC-1295

CJC-1295 (DAC:GRF) / Modified GRF 1-29 · Tetrasubstituted GHRH Analogue · ConjuChem Biotechnologies

Not FDA-approved for any indication. No approved products anywhere in the world. Phase 2 clinical trial (NCT00267527, HIV lipodystrophy, n=192) halted July 2006 following one participant death from myocardial infarction; development discontinued by ConjuChem Biotechnologies. Placed on FDA Category 2 compounding prohibition list 2023; removed September 2024 when nominators withdrew submissions; current compounding status unresolved. WADA prohibited at all times (GHRH analogs, peptide hormones). As of March 2026, remains subject to FDA Pharmacy Compounding Advisory Committee scrutiny.

For research and educational purposes only · Not medical advice · Consult a qualified physician before any human use

Profile Overview

CJC-1295 is a synthetic GHRH analogue developed by ConjuChem Biotechnologies in two forms: CJC-1295 with DAC (half-life 6-8 days, weekly dosing, albumin-binding) and CJC-1295 without DAC / Modified GRF 1-29 (half-life approximately 30 minutes, pulsatile GH release). The primary human evidence is the Teichman 2006 Phase 1 RCT (JCEM) confirming 2-10 fold GH increases and 1.5-3 fold IGF-1 increases sustained for up to 28 days in healthy adults. The pharmaceutical development program was terminated after a Phase 2 death in 2006. It is the most widely used GH secretagogue in research protocols, typically combined with ipamorelin.

🔒

Full Profile: Premium Members Only

The complete CJC-1295 profile includes all use cases with full evidence reviews, mechanism of action deep dive, safety analysis, evidence table, dosing guidance, and stack compatibility data.

For research and educational purposes only · Not medical advice · Consult a qualified physician before any human use